Page 36 - GALENIKA MEDICAL JOURNAL

6. Hook EW, Handsfield HH, Holmes KK, Sparling PF, Stamm WE, Piot P, 23. European Centre for Disease Prevention and Control.
et al. Sexually transmitted diseases. In: Cayla JA, editor. Gonococcal Gonococcal antimicrobial susceptibility surveillance
infections in the adult. 4th ed. New York: McGraw-Hill; 2008. p. 627–45. in Europe, 2016. Stockholm: ECDC; 2018.
7. Morton RS. Gonorrhea: Biological features of Neisseria 24. Day MJ, Spiteri G, Jacobsson S, Woodford N, Amato-Gauci AJ, Cole MJ,
gonorrhoeae. London:W.B. Saunders; 1977:12-60. et al; Euro-GASP network. Stably high azithromycin resistance and
decreasing ceftriaxone susceptibility in Neisseria gonorrhoeae in 25
8. Mahoney JR, Ferguson C, Buchholtz M, van Slyke CJ. The European countries, 2016. BMC Infect Dis. 2018 Dec 3;18(1):609.
use of penicillin sodium in the treatment of sulfonamide-
resistant gonorrhea in men. A preliminary report. Am J 25. Kong FYS, Horner P, Unemo M, Hocking JS. Pharmacokinetic
Syphilis, Gonorrhea, and Venereal Dis. 1943;27:525-8. considerations regarding the treatment of bacterial
sexually transmitted infections with azithromycin: a review.
9. Willcox RR. A survey of problems in the antibiotic J Antimicrob Chemother. 2019 May 1;74(5):1157-66.
treatment of gonorrhoea. With special reference to South-
East Asia. Br J Vener Dis. 1970 Jun;46(3):217-42. 26. Unemo M, Lahra MM, Cole M, Galarza P, Ndowa F, Martin I, et
al. World Health Organization Global Gonococcal Antimicrobial
10. Phillips I. Beta-lactamase-producing, penicillin-resistant Surveillance Program (WHO GASP): review of new data and
gonococcus. Lancet. 1976 Sep 25;2(7987):656-7. evidence to inform international collaborative actions and
11. Schwarcz SK, Zenilman JM, Schnell D, Knapp JS, Hook EW 3rd, research efforts. Sex Health. 2019 Sep;16(5):412-25.
Thompson S, Judson FN, Holmes KK. National surveillance of 27. Rob F, Klubalová B, Nyčová E, Hercogová J, Unemo M. Gentamicin 240
antimicrobial resistance in Neisseria gonorrhoeae. The Gonococcal mg plus azithromycin 2 g vs. ceftriaxone 500 mg plus azithromycin 2
Isolate Surveillance Project. JAMA. 1990 Sep 19;264(11):1413-7. g for treatment of rectal and pharyngeal gonorrhoea: a randomized
12. Tapsall JW, Ndowa F, Lewis DA, Unemo M. Meeting the public health controlled trial. Clin Microbiol Infect. 2020 Feb;26(2):207-12.
challenge of multidrug- and extensively drug-resistant Neisseria 28. Ross JD, Lewis DA. Cephalosporin resistant Neisseria gonorrhoeae:
gonorrhoeae. Expert Rev Anti Infect Ther. 2009 Sep;7(7):821-34. time to consider gentamicin? Sex Transm Infect. 2012 Feb;88(1):6-8.
13. Tapsall JW. Antibiotic resistance in Neisseria gonorrhoeae. 29. Golparian D, Fernandes P, Ohnishi M, Jensen JS, Unemo M. In vitro
Clin Infect Dis. 2005 Aug 15;41 (Suppl 4):S263-8. activity of the new fluoroketolide solithromycin (CEM-101) against
14. Centers for Disease Control and Prevention (CDC). Update to a large collection of clinical Neisseria gonorrhoeae isolates and
international reference strains, including those with high-level
CDC’s sexually transmitted diseases treatment guidelines, 2006: antimicrobial resistance: potential treatment option for gonorrhea?
fluoroquinolones no longer recommended for treatment of gonococcal Antimicrob Agents Chemother. 2012 May;56(5):2739-42.
infections. MMWR Morb Mortal Wkly Rep. 2007 Apr 13;56(14):332-6.
15. Bignell C, Garley J. Azithromycin in the treatment of infection with 30. Still JG, Schranz J, Degenhardt TP, Scott D, Fernandes P,
Neisseria gonorrhoeae. Sex Transm Infect. 2010 Nov;86(6):422-6. Gutierrez MJ, et al. Pharmacokinetics of solithromycin (CEM-
101) after single or multiple oral doses and effects of food
16. Chisholm SA, Neal TJ, Alawattegama AB, Birley HD, on single-dose bioavailability in healthy adult subjects.
Howe RA, Ison CA. Emergence of high-level azithromycin Antimicrob Agents Chemother. 2011 May;55(5):1997-2003.
resistance in Neisseria gonorrhoeae in England and Wales.
J Antimicrob Chemother. 2009 Aug;64(2):353-8. 31. Unemo M, Golparian D, Limnios A, Whiley D, Ohnishi M, Lahra
MM, et al. In vitro activity of ertapenem versus ceftriaxone
17. Akasaka S, Muratani T, Yamada Y, Inatomi H, Takahashi K, against Neisseria gonorrhoeae isolates with highly diverse
Matsumoto T. Emergence of cephem- and aztreonam-high- ceftriaxone MIC values and effects of ceftriaxone resistance
resistant Neisseria gonorrhoeae that does not produce beta- determinants: ertapenem for treatment of gonorrhea?
lactamase. J Infect Chemother. 2001 Mar;7(1):49-50. Antimicrob Agents Chemother. 2012 Jul;56(7):3603-9.
18. Unemo M, Golparian D, Syversen G, Vestrheim DF, Moi H. 32. Fifer H, Saunders J, Soni S, Sadiq ST, FitzGerald M. 2018 UK
Two cases of verified clinical failures using internationally national guideline for the management of infection with
recommended first-line cefixime for gonorrhoea treatment, Neisseria gonorrhoeae. Int J STD AIDS. 2020 Jan;31(1):4-15.
Norway, 2010. Euro Surveill. 2010 Nov 25;15(47):19721.
19. Ohnishi M, Golparian D, Shimuta K, Saika T, Hoshina S,
Iwasaku K, et al. Is Neisseria gonorrhoeae initiating a future
era of untreatable gonorrhea?: detailed characterization
of the first strain with high-level resistance to ceftriaxone.
Antimicrob Agents Chemother. 2011 Jul;55(7):3538-45. Konflikt interesa: Nema
20. Unemo M, Golparian D, Nicholas R, Ohnishi M, Gallay A, Primljeno: 01. 02. 2022.
Sednaoui P. High-level cefixime- and ceftriaxone-resistant Prihvaćeno: 18. 03. 2022.
Neisseria gonorrhoeae in France: novel penA mosaic allele
in a successful international clone causes treatment failure. Onlajn: 30. 06. 2022.
Antimicrob Agents Chemother. 2012 Mar;56(3):1273-80.
21. Fyle-Thorpe O. Chlamydia and Gonorrhea: An Update,
The Journal for Nurse Practitioners. 2019;15:424-8.
22. Fairley CK, Cornelisse VJ, Hocking JS, Chow EPF. Models
of gonorrhoea transmission from the mouth and
saliva. Lancet Infect Dis. 2019 Oct;19(10):e360-6.

36 DOI: 10.5937/Galmed2202032G